Treatment of osteoporosis in peri- and post-menopausal women with hepcidin

• US 8,999,935 B2
• Filed: 02/11/2010
• Issued: 04/07/2015
• Est. Priority Date: 02/11/2009
• Status: Active Grant

• Current Assignee: New York University
• Original Assignee: New York University
• Inventors: Huang, Xi
• Primary Examiner(s): Xie, Xiaozhen
• Application Number:
  US12/704,187
• Publication Number:
  US 20100204122A1
• Time in Patent Office: 1,881 Days
• Field of Search: None
• US Class Current: 514/16.7
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis

Abstract

The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.

Claims

1. A method of treating bone deterioration or osteoporosis in a peri- or post-menopausal female subject, said method comprising:

selecting a peri- or post-menopausal female subject having bone deterioration or osteoporosis, and

administering a hepcidin polypeptide to the selected subject under conditions effective to treat bone density or osteoporosis wherein the hepcidin polypeptide has the amino acid sequence of SEQ ID NO;

2.

2. The method according to claim 1, wherein the hepcidin polypeptide is human hepcidin.

3. The method according to claim 1, wherein the bone deterioration is in the form of a change in bone micro-architecture, decrease in calcium bioavailability, decrease in bone calcification rates, decrease in bone formation rates, decrease in osteoblast proliferation rates, decrease in differentiation rate of osteoblasts, and/or osteopeonia.

4. The method according to claim 1, wherein the subject is a mammal.

5. The method according to claim 1, wherein the subject is a human.

6. The method according to claim 1, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, or by application to mucous membranes.

7. The method according to claim 1, wherein the hepcidin is administered as a tablet, capsule, powder, solution, colloid, suspension, or emulsion.